Prothena (PRTA) Projected to Release Earnings on Thursday

Key Points

• Prothena is expected to report Q3 2026 results after market close on November 5, with analysts projecting a loss of $0.2271 per share and revenue of $9.58 million.
• In its prior quarter, Prothena posted a smaller-than-expected loss of $0.32 per share and revenue of $1.01 million, while maintaining negative profitability metrics.
• Analyst sentiment is broadly positive but mixed, with a “Moderate Buy” consensus and an average price target of $20 versus the stock’s recent price near $9.10; insiders have also purchased more than 1 million shares over the past 90 days.

Prothena (NASDAQ:PRTA - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.2271) per share and revenue of $9.58 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Prothena (NASDAQ:PRTA - Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07. Prothena had a negative return on equity of 16.45% and a negative net margin of 80.68%. The firm had revenue of $1.01 million for the quarter, compared to analyst estimates of $0.42 million. On average, analysts expect Prothena to post $0.08 EPS for the current fiscal year and ($1.13) EPS for the next fiscal year.

Prothena Trading Up 3.3%

Shares of PRTA opened at $9.10 on Thursday. Prothena has a 1 year low of $7.73 and a 1 year high of $11.80. The stock has a market cap of $476.41 million, a P/E ratio of -10.83, a price-to-earnings-growth ratio of 2.89 and a beta of -0.29. The stock's 50-day moving average price is $8.78 and its two-hundred day moving average price is $9.23.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PRTA. Wall Street Zen cut Prothena from a "buy" rating to a "hold" rating in a research note on Saturday, July 25th. UBS Group reissued a "buy" rating on shares of Prothena in a research note on Friday, July 24th. Weiss Ratings raised shares of Prothena from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, October 14th. Finally, HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Prothena in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $20.00.

Insiders Place Their Bets

In other Prothena news, major shareholder William P. Scully bought 162,000 shares of the firm's stock in a transaction on Tuesday, September 29th. The stock was purchased at an average cost of $8.68 per share, with a total value of $1,406,160.00. Following the completion of the purchase, the insider owned 214,000 shares in the company, valued at approximately $1,857,520. The trade was a 311.54% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders bought 1,017,500 shares of company stock worth $8,654,850 in the last 90 days. Insiders own 10.40% of the company's stock.

About Prothena

Prothena Corporation plc NASDAQ: PRTA is a clinical-stage biotechnology company focused on discovering and developing novel medicines for serious neurodegenerative and rare peripheral diseases. Its research is centered on disease-causing proteins, including amyloid-beta, alpha-synuclein and transthyretin, with the goal of creating antibody-based therapies that address underlying disease mechanisms.

The company's product pipeline has included birtamimab, an investigational antibody being developed for the treatment of AL amyloidosis, and prasinezumab, an investigational alpha-synuclein antibody being developed in collaboration with Roche for certain forms of Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.